Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis
Richard H Kimura, Ling Wang, Bin Shen, Li Huo, Willemieke Tummers, Fabian V Filipp, Haiwei Henry Guo, Thomas Haywood, Lotfi Abou-Elkacem, Lucia Baratto, Frezghi Habte, Rammohan Devulapally, Timothy H Witney, Yan Cheng, Suhas Tikole, Subhendu Chakraborti, Jay Nix, Christopher A Bonagura, Negin Hatami, Joshua J Mooney, Tushar Desai, Scott Turner, Richard S Gaster, Andrea Otte, Brendan C Visser, George A Poultsides, Jeffrey Norton, Walter Park, Mark Stolowitz, Kenneth Lau, Eric Yang, Arutselvan Natarajan, Ohad Ilovich, Shyam Srinivas, Ananth Srinivasan, Ramasamy Paulmurugan, Juergen Willmann, Frederick T Chin, Zhen Cheng, Andrei Iagaru, Fang Li, Sanjiv S Gambhir, Richard H Kimura, Ling Wang, Bin Shen, Li Huo, Willemieke Tummers, Fabian V Filipp, Haiwei Henry Guo, Thomas Haywood, Lotfi Abou-Elkacem, Lucia Baratto, Frezghi Habte, Rammohan Devulapally, Timothy H Witney, Yan Cheng, Suhas Tikole, Subhendu Chakraborti, Jay Nix, Christopher A Bonagura, Negin Hatami, Joshua J Mooney, Tushar Desai, Scott Turner, Richard S Gaster, Andrea Otte, Brendan C Visser, George A Poultsides, Jeffrey Norton, Walter Park, Mark Stolowitz, Kenneth Lau, Eric Yang, Arutselvan Natarajan, Ohad Ilovich, Shyam Srinivas, Ananth Srinivasan, Ramasamy Paulmurugan, Juergen Willmann, Frederick T Chin, Zhen Cheng, Andrei Iagaru, Fang Li, Sanjiv S Gambhir
Abstract
Advances in precision molecular imaging promise to transform our ability to detect, diagnose and treat disease. Here, we describe the engineering and validation of a new cystine knot peptide (knottin) that selectively recognizes human integrin αvβ6 with single-digit nanomolar affinity. We solve its 3D structure by NMR and x-ray crystallography and validate leads with 3 different radiolabels in pre-clinical models of cancer. We evaluate the lead tracer's safety, biodistribution and pharmacokinetics in healthy human volunteers, and show its ability to detect multiple cancers (pancreatic, cervical and lung) in patients at two study locations. Additionally, we demonstrate that the knottin PET tracers can also detect fibrotic lung disease in idiopathic pulmonary fibrosis patients. Our results indicate that these cystine knot PET tracers may have potential utility in multiple disease states that are associated with upregulation of integrin αvβ6.
Conflict of interest statement
The authors declare no competing interests.
Figures
References
- Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL.
- Saini G, et al. alphavbeta6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur. Respir. J. 2015;46:486–494. doi: 10.1183/09031936.00210414.
- Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev. Cell Dev. Biol. 1996;12:297–715. doi: 10.1146/annurev.cellbio.12.1.697.
- Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res. 2009;69:2435–2442. doi: 10.1158/0008-5472.CAN-08-2495.
- Haubner R, Maschauer S, Prante O. PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments. Biomed. Res Int. 2014;2014:1–17.
- Gaertner FC, Kessler H, Wester HJ, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur. J. Nucl. Med. Mol. imaging. 2012;39:126–138. doi: 10.1007/s00259-011-2028-1.
- Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–687. doi: 10.1016/S0092-8674(02)00971-6.
- Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010;10:9–22. doi: 10.1038/nrc2748.
- Reed NI, et al. The alphavbeta1 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl. Med. 2015;7:288ra279. doi: 10.1126/scitranslmed.aaa5094.
- Kingwell K. Fibrotic diseases: New tools to target an elusive integrin. Nat. Rev. Drug Discov. 2015;14:460. doi: 10.1038/nrd4672.
- Henderson NC, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 2013;19:1617–1624. doi: 10.1038/nm.3282.
- Chen H, Niu G, Wu H, Chen X. Clinical application of radiolabeled RGD peptides for PET imaging of integrin alphavbeta3. Theranostics. 2016;6:78–92. doi: 10.7150/thno.13242.
- John AE, et al. Preclinical SPECT/CT imaging of alphavbeta6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 2013;54:2146–2152. doi: 10.2967/jnumed.113.120592.
- Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr. Drug Targets. 2009;10:645–652. doi: 10.2174/138945009788680374.
- Breuss JM, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J. Cell Sci. 1995;108:2241–2251.
- Sipos B, et al. Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology. 2004;45:226–236. doi: 10.1111/j.1365-2559.2004.01919.x.
- Maubant S, et al. Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J. Mol. Histol. 2005;36:119–129. doi: 10.1007/s10735-004-4273-0.
- Orimoto AM, et al. High numbers of human skin cancers express MMP2 and several integrin genes. J. Cutan. Pathol. 2008;35:285–291. doi: 10.1111/j.1600-0560.2007.00810.x.
- Bates RC, et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J. Clin. Invest. 2005;115:339–347. doi: 10.1172/JCI200523183.
- Elayadi AN, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007;67:5889–5895. doi: 10.1158/0008-5472.CAN-07-0245.
- Hazelbag S, et al. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. J. Pathol. 2007;212:316–324. doi: 10.1002/path.2168.
- Zhang ZY, et al. Integrin alphanvbeta6 acts as a prognostic indicator in gastric carcinoma. Clin. Oncol. (R. Coll. Radio.). 2008;20:61–66. doi: 10.1016/j.clon.2007.09.008.
- Yang GY, et al. Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. Cancer Sci. 2008;99:879–887. doi: 10.1111/j.1349-7006.2008.00762.x.
- Tummers, W. S. et al. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget8, 56816–56828 (2017).
- Hausner SH, DiCara D, Marik J, Marshall JF, Sutcliffe JL. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. Cancer Res. 2007;67:7833–7840. doi: 10.1158/0008-5472.CAN-07-1026.
- Kimura RH, et al. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin. Cancer Res. 2012;18:839–849. doi: 10.1158/1078-0432.CCR-11-1116.
- Altmann A, et al. Identification of a Novel ITGalphavbeta6-Binding Peptide Using Protein Separation and Phage Display. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2017;23:4170–4180. doi: 10.1158/1078-0432.CCR-16-3217.
- Horan GS, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. care Med. 2008;177:56–65. doi: 10.1164/rccm.200706-805OC.
- Munger JS, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999;96:319–328. doi: 10.1016/S0092-8674(00)80545-0.
- Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem. 1986;261:4337–4345.
- Kimura RH, Levin AM, Cochran FV, Cochran JR. Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins. 2009;77:359–369. doi: 10.1002/prot.22441.
- Hackel BJ, Kimura RH, Gambhir SS. Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. Radiology. 2012;263:179–188. doi: 10.1148/radiol.12111504.
- Colgrave ML, Craik DJ. Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. Biochemistry. 2004;43:5965–5975. doi: 10.1021/bi049711q.
- Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol. Bull. 1979;86:420–428. doi: 10.1037/0033-2909.86.2.420.
- Reed CE, Barbee RA. Pigeon-breeders’ lung: a newly observed interstitial pulmonary disease. Jama. 1965;193:261–265. doi: 10.1001/jama.1965.03090040005001.
- Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin. Epidemiol. 2013;5:483–492. doi: 10.2147/CLEP.S54815.
- Xiong JP, et al. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Sci. (New Y., N. Y.) 2002;296:151–155. doi: 10.1126/science.1069040.
- Hausner SH, Bauer N, Hu LY, Knight LM, Sutcliffe JL. The effect of bi-terminal PEGylation of an integrin alphavbeta(6)-targeted (1)(8)F peptide on pharmacokinetics and tumor uptake. J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 2015;56:784–790. doi: 10.2967/jnumed.114.150680.
- Kraft S, et al. Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J. Biol. Chem. 1999;274:1979–1985. doi: 10.1074/jbc.274.4.1979.
- Nothelfer EM, et al. Identification and characterization of a peptide with affinity to head and neck cancer. J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 2009;50:426–434. doi: 10.2967/jnumed.108.058123.
- Willmann JK, et al. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 2010;51:433–440. doi: 10.2967/jnumed.109.068007.
- Zhang C, et al. A cystine knot peptide targeting integrin alphavbeta6 for photoacoustic and fluorescence imaging of tumors in living subjects. J. Nucl. Med.: Off. Publ., Soc. Nucl. Med. 2016;57:1629–1634. doi: 10.2967/jnumed.115.169383.
- Chin FT, et al. First experience with clinical-grade ([18F]FPP(RGD(2)): an automated multi-step radiosynthesis for clinical PET studies. Mol. Imaging Biol.: MIB: Off. Publ. Acad. Mol. Imaging. 2012;14:88–95. doi: 10.1007/s11307-011-0477-3.
- Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. The journal of histochemistry and cytochemistry: official journal of the Histochemistry. Society. 1993;41:1521–1527.
- Sheppard D. Roles of alphav integrins in vascular biology and pulmonary pathology. Curr. Opin. cell Biol. 2004;16:552–557. doi: 10.1016/j.ceb.2004.06.017.
- Henderson NC, Sheppard D. Integrin-mediated regulation of TGFbeta in fibrosis. Biochim. et. Biophys. acta. 2013;1832:891–896. doi: 10.1016/j.bbadis.2012.10.005.
- Popov Y, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J. Hepatol. 2008;48:453–464. doi: 10.1016/j.jhep.2007.11.021.
- Conroy KP, Kitto LJ, Henderson NC. alphav integrins: key regulators of tissue fibrosis. Cell tissue Res. 2016;365:511–519. doi: 10.1007/s00441-016-2407-9.
- Raghu, G. et al. American Thoracic Society: ATS Conference 2018 (San Diego CA USA, 2018).
- Slack, R. J. et al. The International Colloquim on Lung and Airway Fibrosis (ICLAF). (Dublin, Ireland, 2016).
- Rosas IO, et al. Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann. Am. Thorac. Soc. 2014;11(Suppl 3):S169–S177. doi: 10.1513/AnnalsATS.201312-429LD.
- Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am. J. Respir. Crit. care Med. 2012;185:1147–1153. doi: 10.1164/rccm.201108-1420PP.
- Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 2010;11:97–105. doi: 10.1038/embor.2009.276.
- Farnoud MR, Veirana N, Derome P, Peillon F, Li JY. Adenomatous transformation of the human anterior pituitary is associated with alterations in integrin expression. Int. J. cancer. 1996;67:45–53. doi: 10.1002/(SICI)1097-0215(19960703)67:1<45::AID-IJC10>;2-B.
- Recouvreux MV, Camilletti MA, Rifkin DB, Diaz-Torga G. The pituitary TGFbeta1 system as a novel target for the treatment of resistant prolactinomas. J. Endocrinol. 2016;228:R73–R83. doi: 10.1530/JOE-15-0451.
- Farrell WE. Pituitary tumours: findings from whole genome analyses. Endocr.-Relat. cancer. 2006;13:707–716. doi: 10.1677/erc.1.01131.
- Paulus W, Baur I, Schuppan D, Roggendorf W. Characterization of integrin receptors in normal and neoplastic human brain. Am. J. Pathol. 1993;143:154–163.
- Ying SY, et al. Type beta transforming growth factor (TGF-beta) is a potent stimulator of the basal secretion of follicle stimulating hormone (FSH) in a pituitary monolayer system. Biochem. Biophys. Res. Commun. 1986;135:950–956. doi: 10.1016/0006-291X(86)91020-X.
- Fujiwara K, Ikeda H, Yoshimoto T. Immunohistochemical demonstration of TGF-beta-receptor type II in human pituitary adenomas. Acta Histochem. 1995;97:445–454. doi: 10.1016/S0065-1281(11)80071-1.
- Munger JS, Sheppard D. Cross talk among TGF-beta signaling pathways, integrins, and the extracellular matrix. Cold Spring Harb. Perspect. Biol. 2011;3:a005017. doi: 10.1101/cshperspect.a005017.
- Stabin MG, Sparks Rb Fau - Crowe E, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 2005;46:1023–1027.
- Kimura RH, Cheng Z, Gambhir SS, Cochran JR. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res. 2009;69:2435–2442. doi: 10.1158/0008-5472.CAN-08-2495.
- Filipp FabianV, Sattler Michael. Conformational Plasticity of the Lipid Transfer Protein SCP2. Biochemistry. 2007;46:7980–7991. doi: 10.1021/bi6025616.
- Filipp FabianV, Scott DavidA, Ronai Ze’evA, Osterman AndreiL, Smith JeffreyW. Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell & Melanoma Research. 2012;25:375–383. doi: 10.1111/j.1755-148X.2012.00989.x.
- Alice Douangamath FabianV, et al. Topography for Independent Binding of α-Helical and PPII-Helical Ligands to a Peroxisomal SH3 Domain. Molecular Cell. 2002;10:1007–1017. doi: 10.1016/S1097-2765(02)00749-9.
- Stanley WillA, et al. Recognition of a Functional Peroxisome Type 1 Target by the Dynamic Import Receptor Pex5p. Molecular Cell. 2006;24:653–663. doi: 10.1016/j.molcel.2006.10.024.
- Shannon L, et al. Probing lipid- and drug-binding domains with fluorescent dyes. Bioorganic & Medicinal Chemistry. 2008;16:1162–1173. doi: 10.1016/j.bmc.2007.10.080.
- Delaglio, F. et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes. Journal of Biomolecular NMR, (1995) 6
- Johnson BruceA, Blevins RichardA. NMR View: A computer program for the visualization and analysis of NMR data. Journal of Biomolecular NMR. 1994;4:603–614. doi: 10.1007/BF00404272.
- Peng C, Unger SW, Filipp FV, Sattler M, Szalma S. Automated evaluation of chemical shift perturbation spectra: New approaches to quantitative analysis of receptor-ligand interaction NMR spectra. J Biomol NMR. 2004;29:491–504. doi: 10.1023/B:JNMR.0000034351.37982.9e.
- Filipp FabianV, Sinha Neeraj, Jairam Lena, Bradley Joel, Opella StanleyJ. Labeling strategies for 13C-detected aligned-sample solid-state NMR of proteins. Journal of Magnetic Resonance. 2009;201:121–130. doi: 10.1016/j.jmr.2009.08.012.
- Scott DavidA, et al. Comparative Metabolic Flux Profiling of Melanoma Cell Lines. Journal of Biological Chemistry. 2011;286:42626–42634. doi: 10.1074/jbc.M111.282046.
- Günert P. Automated NMR structure calculation with CYANA. Methods Mol Biol. 2004;278:353–378. doi: 10.1385/1-59259-809-9:353.
- Thompson AC, Westbrook EM, Lavender WM, Nix JC. A large area CMOS detector for shutterless collection of x-ray diffraction data. J. Phys.: Conf. Ser. 2014;493:012019.
- Kabsch W. XDS. Acta Crystallogr. Sect. D. 2010;D66:125–132. doi: 10.1107/S0907444909047337.
- Collaborative_Computational_Project. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D. Biol. Crystallogr. 1994;50:760–763. doi: 10.1107/S0907444994003112.
- Adams Paul D., Grosse-Kunstleve Ralf W., Hung Li-Wei, Ioerger Thomas R., McCoy Airlie J., Moriarty Nigel W., Read Randy J., Sacchettini James C., Sauter Nicholas K., Terwilliger Thomas C. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallographica Section D Biological Crystallography. 2002;58(11):1948–1954. doi: 10.1107/S0907444902016657.
- McCoy Aj, et al. Phaser crystallographic software. J. Appl. Crystallogr. 2007;40:658–674. doi: 10.1107/S0021889807021206.
- Perrakis A., Harkiolaki M., Wilson K. S., Lamzin V. S. ARP/wARP and molecular replacement. Acta Crystallogr. D 57, 1445-1450 (2001).
- Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).
Source: PubMed